Savient resubmits Krystexxa BLA

Savient Pharmaceuticals Inc. (NASDAQ:SVNT) resubmitted a BLA to FDA for Krystexxa pegloticase to treat chronic refractory gout. Savient said the resubmission addresses issues raised by FDA in a July 2...